Filtered By:
Source: American Heart Journal
Condition: Heart Attack
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 253 results found since Jan 2013.
Clinical outcomes after hybrid coronary revascularization versus coronary artery bypass surgery: a meta-analysis of 1,190 patients
Conclusions: Hybrid coronary revascularization is associated with lower morbidity and similar in-hospital and 1-year major adverse cerebrovascular or cardiac events rates, but greater requirement for repeat revascularization compared with CABG. Further exploration of this strategy with adequately powered randomized trials is warranted.
Source: American Heart Journal - January 30, 2014 Category: Cardiology Authors: Ralf E. Harskamp, Akshay Bagai, Michael E. Halkos, Sunil V. Rao, William B. Bachinsky, Manesh R. Patel, Robbert J. de Winter, Eric D. Peterson, John H. Alexander, Renato D. Lopes Tags: Interventional Cardiology Source Type: research
Sex difference in clinical outcomes after percutaneous coronary intervention in Korean population
Conclusion: Among Korean population undergoing contemporary PCI, women have a significantly higher risk of short- and long-term major cardiovascular events than do men but have better long-term survival.
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: Duk-Woo Park, Young-Hak Kim, Sung-Cheol Yun, Jung-Min Ahn, Jong-Young Lee, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park Tags: Interventional Cardiology Source Type: research
Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen—Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study
Background: An increasing number of patients undergoing coronary stenting need lifelong anticoagulation and therefore require a triple therapy typically consisting of aspirin, clopidogrel, and a vitamin K antagonist. Triple therapy confers an elevated bleeding risk as compared with dual therapy; however, omission of either antiplatelet or anticoagulation therapy might increase the risk of stent thrombosis or thrombembolic events. Although guidelines recommend a duration of dual antiplatelet therapy of 6 to 12months after drug-eluting stent (DES) implantation, the optimal duration of dual antiplatelet therapy in patients re...
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: K. Anette Fiedler, Robert A. Byrne, Stefanie Schulz, Dirk Sibbing, Julinda Mehilli, Tareq Ibrahim, Michael Maeng, Karl-Ludwig Laugwitz, Adnan Kastrati, Nikolaus Sarafoff Tags: Trial Design Source Type: research
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial
Conclusions: PEGASUS-TIMI 54 is investigating whether the addition of intensive antiplatelet therapy with ticagrelor to low-dose aspirin reduces major adverse cardiovascular events in high-risk patients with a history of myocardial infarction.
Source: American Heart Journal - January 8, 2014 Category: Cardiology Authors: Marc P. Bonaca, Deepak L. Bhatt, Eugene Braunwald, Marc Cohen, Philippe Gabriel Steg, Robert F. Storey, Peter Held, Eva C. Jensen, Marc S. Sabatine Tags: Trial Design Source Type: research
Association of the ankle-brachial index with history of myocardial infarction and stroke
Background: Ankle-brachial index (ABI) testing is a simple, noninvasive method to diagnose peripheral artery disease (PAD) and is associated with all-cause mortality. The association of ABI levels and myocardial infarction (MI) and stroke is less certain. We sought to further characterize the association between ABI levels and history of MI and stroke.Methods: Using data from the Life Line Screening program, 3.6 million self-referred participants from 2003 to 2008 completed a medical questionnaire and had bilateral ABIs performed. Logistic regression was used to estimate the association between ABI cutoff points (ABI 1.40)...
Source: American Heart Journal - January 6, 2014 Category: Cardiology Authors: W. Schuyler Jones, Manesh R. Patel, Caron B. Rockman, Yu Guo, Mark Adelman, Thomas Riles, Jeffrey S. Berger Tags: Peripheral Vascular Disease Source Type: research
Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study)
Background: Growth differentiation factor 15 (GDF-15) is a relatively new biomarker that predicts mortality in patients with chronic stable angina or acute coronary syndrome. However, the association of GDF-15 with cardiovascular (CV) events and the mechanisms of this association are not well understood.Methods: We measured plasma GDF-15 and cardiac disease severity in 984 patients with stable ischemic heart disease who were recruited for the Heart and Soul Study between September 2000 and December 2002. Subsequent CV events (myocardial infarction, stroke, and CV death), hospitalization for heart failure, and all-cause mor...
Source: American Heart Journal - December 9, 2013 Category: Cardiology Authors: David W. Schopfer, Ivy A. Ku, Mathilda Regan, Mary A. Whooley Tags: Coronary Artery Disease Source Type: research
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. TECOS will evaluate the effects of adding sitagliptin to usual diabetes care on cardiovascular outcomes and clinical safety. TECOS is a pragmatic, academically run, multinational, randomized, double-blind, placebo-controlled, event-driven trial recruiting approximately 14,000 patients in 38 countries who have type 2 diabetes (T2DM), are at least 50 years old, have cardiovascular disease, and have an hemoglobin A1c value between 6.5% and 8.0%. Eligible participan...
Source: American Heart Journal - October 25, 2013 Category: Cardiology Authors: Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, Rury R. Holman Tags: Trial Design Source Type: research
Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial
Conclusions: RIVER-PCI is a novel, large-scale, international, randomized, double-blind, placebo-controlled clinical trial evaluating the role of ranolazine in the long-term medical management of patients with ICR post-PCI.
Source: American Heart Journal - October 18, 2013 Category: Cardiology Authors: Giora Weisz, Ramin Farzaneh-Far, Ori Ben-Yehuda, Bernard DeBruyne, Gilles Montalescot, Amir Lerman, Ehtisham Mahmud, Karen P. Alexander, E. Magnus Ohman, Harvey D. White, Ann Olmsted, Gennyne A. Walker, Gregg W. Stone Tags: Trial Design Source Type: research
Radial versus femoral approach comparison in percutaneous coronary intervention with intraaortic balloon pump support: The RADIAL PUMP UP Registry
Background: The role of intraaortic balloon pump (IABP) during percutaneous coronary intervention (PCI) in high-risk acute patients remains debated. Device-related complications and the more complex patient management could explain such lack of clinical benefit. We aimed to assess the impact of transradial versus transfemoral access for PCI requiring IABP support on vascular complications and clinical outcome.Methods: We retrospectively analyzed 321 consecutive patients receiving IABP support during transfemoral (n = 209) or transradial (n = 112) PCI. Thirty-day net adverse clinical events (NACEs) (composite of postprocedu...
Source: American Heart Journal - October 14, 2013 Category: Cardiology Authors: Enrico Romagnoli, Maria De Vita, Francesco Burzotta, Bernardo Cortese, Giuseppe Biondi-Zoccai, Francesco Summaria, Roberto Patrizi, Chiara Lanzillo, Valerio Lucci, Caterina Cavazza, Fabio Tarantino, Giuseppe M. Sangiorgi, Ernesto Lioy, Filippo Crea, Sunil Tags: Interventional Cardiology Source Type: research
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Conclusions: LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Source: American Heart Journal - October 4, 2013 Category: Cardiology Authors: Steven P. Marso, Neil R. Poulter, Steven E. Nissen, Michael A. Nauck, Bernard Zinman, Gilbert H. Daniels, Stuart Pocock, William M. Steinberg, Richard M. Bergenstal, Johannes F.E. Mann, Lasse Steen Ravn, Kirstine Brown Frandsen, Alan C. Moses, John B. Bus Tags: Trial Design Source Type: research
Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: Design of the MUSICA-2 randomized trial
Conclusions: The MUSICA-2 will attempt to determine the most effective and safe treatment in patients with nonvalvular AF and CHADS2 score ≤2 after PCI-S. Restricting TT for AF patients at high risk for stroke may reduce the incidence of bleeding without increasing the risk of thromboembolic complications.
Source: American Heart Journal - September 16, 2013 Category: Cardiology Authors: Antonia Sambola, J. Bruno Montoro, Bruno García del Blanco, Nadia Llavero, José A. Barrabés, Fernando Alfonso, Héctor Bueno, Angel Cequier, Antonio Serra, Javier Zueco, Manel Sabaté, Oriol Rodríguez-Leor, David García-Dorado Tags: Trial Design Source Type: research
Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation
Conclusions: Cardiovascular hospitalization is common in the first year after AF diagnosis. Atrial fibrillation, heart failure, myocardial infarction, and stroke/transient ischemic attack account for half of primary hospitalization diagnosis. Cardiovascular hospitalization is independently associated with mortality, irrespective of time from diagnosis to first hospitalization, and represents a critical inflection point in survival trajectory. These findings highlight the importance of CV hospitalization as a marker of disease progression and poor outcomes. Efforts to clarify the determinants of hospitalization could inform...
Source: American Heart Journal - August 12, 2013 Category: Cardiology Authors: Mintu P. Turakhia, Matthew D. Solomon, Mehul Jhaveri, Pamela Davis, Michael R. Eber, Ryan Conrad, Nicholas Summers, Darius Lakdawalla Tags: Electrophysiology Source Type: research
Change in enrollment patterns, patient selection, and clinical outcomes with the availability of drug-eluting stents in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial
Background: In the BARI 2D trial, patients with type 2 diabetes and stable coronary artery disease were randomized to prompt revascularization versus intensive medical therapy (IMT). This analysis sought to evaluate how the availability of drug-eluting stents (DESs) has changed practice and outcomes.Methods: In BARI 2D, 1,605 patients were in the percutaneous coronary intervention (PCI)–intended stratum. As DES became available midway through recruitment, we report clinical outcomes among patients who underwent IMT versus prompt PCI with bare-metal stents (BMSs) or DES up to 4 years.Results: In North America, after DES b...
Source: American Heart Journal - August 7, 2013 Category: Cardiology Authors: Binita Shah, Vankeepuram S. Srinivas, Jiang Lu, Maria M. Brooks, Eric R. Bates, Zoran S. Nedeljkovic, Jorge Escobedo, Gladwin S. Das, John J. Lopez, Frederick Feit Tags: Interventional Cardiology Source Type: research
